[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632685":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":19,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":19,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":19,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":19,"overallStatus":62,"whyStopped":19,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Luye Pharma Group Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[14C] LPM3770164","EXPERIMENTAL","20 mg\u002F150 µCi \\[14C\\] LPM3770164",[13],"Drug: [14C] LPM3770164",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","The subjects are required to take 20 mg\u002F150 µCi \\[14C\\] LPM3770164 tablet (s) in the fasted state with a total of approximately 240 mL of water to ensure completion within 5 minutes",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"yiqing Zhao, Doctor","CONTACT","+8613358100007","13358100007@126.com",[27],{"facility":28,"status":19,"city":29,"state":30,"zip":19,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Affiliated Hospital of Jiangnan University","Wuxi","Jiangsu","China","CN",{"type":34,"coordinates":35},"Point",[36,37],120.28857,31.56887,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":42,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100632685","phase-1-mass-balance-study-of-14c-lpm3770164-in-healthy-participants-100632685",false,"NCT07516899","Mass Balance Study of [14C] LPM3770164 in Healthy Participants","Inclusion Criteria:\n\n1. Healthy adult Chinese males;\n2. Age at informed consent: 18-45 years (including boundary value);\n3. Body mass index (BMI) range of 19-26 kg\u002Fm2 (including the boundary value), and body weight of not less than 50 kg;\n4. There is no plan to have children or donate sperm within 1 year after the participant signs the informed consent form and the participant voluntarily takes strict contraceptive measures within 1 year after signing the informed consent form and completing the trial;\n5. Fully understand the purpose and requirements of this study, and voluntarily sign the informed consent form;\n6. Able to communicate well with the investigators and be able to complete the trial according to the protocol.\n\nExclusion Criteria:\n\n1. Abnormal and clinically significant vital signs, physical examination, chest X-ray (anteroposterior), ophthalmic examination, anal digital examination and abdominal B ultrasound examination;\n2. Abnormal laboratory examination during the screening period, and clinically significant according to the investigator's judgment:\n3. QTcF interval \\> 450 ms in men; or other abnormalities are clinically significant in the judgment of the investigator;\n4. Abnormal tests of hepatitis B surface antigen, hepatitis C virus antibody IgG (Anti-HCV IgG), treponema pallidum antibody and human immunodeficiency virus antibody are clinically significant at the investigator's discretion;\n5. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicine, food supplements within 4 weeks prior to screening;\n6. Use of any drugs that inhibit or induce hepatic drug metabolizing enzyme activity within 4 weeks prior to screening;\n7. History of any clinically significant disease or disease or condition that may affect the results of the trial;\n8. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsades de pointes, tachycardia, atrioventricular block, QT prolongation syndrome or a family history of QT prolongation syndrome symptoms;\n9. . Patients with dysphagia, esophageal stenosis or gastrointestinal diseases that cause clinically significant symptoms or with a history of severe vomiting and diarrhea in the week prior screening;\n10. Patients who previously underwent surgery that would affect the absorption, distribution, metabolism and excretion of drugs, or had undergone major surgery or had incomplete healing of surgical incision within 6 months prior to the screening period; or planned to undergo surgery during the study period;\n11. History of drug, food, or environmental allergy, especially to components similar to the investigational product, or a known allergic constitution;\n12. Patients with symptomatic hemorrhoids or diseases accompanied by regular\u002Fongoing hematochezia, irritable bowel syndrome, and inflammatory bowel disease;\n13. History of congenital or acquired urinary tract stenosis, prostatic hyperplasia, or abnormal bladder function;\n14. Habitual diarrhea or average bowel movement frequency less than once daily;\n15. Alcoholics or regular drinkers within 6 months before screening, that is, drinking more than 14 units of alcohol per week, or alcohol breath test results \\> 0 mg\u002F100ml at screening, or drinkers within 48 hours before the use of the test drug, or unable to abstain from alcohol during the test;\n16. The average daily smoking amount in the 3 months before screening is greater than 5 cigarettes or habitual use of nicotine-containing products, or unable to abstain during the trial;\n17. Previous history of drug abuse or drug abuse, or positive urine drug abuse screening;\n18. Excessive consumption of tea, coffee and\u002For caffeine-rich beverages, grapefruit juice and other beverages that affect liver enzyme activity per day within 3 months before screening, or inability to abstain during the trial;\n19. Those with special requirements for diet or failing to comply with the unified diet;\n20. Those who plan to have strenuous exercise during the trial;\n21. Workers engaged in long-term exposure to radioactive conditions, or those with significant radioactive exposure;\n22. Blood loss or blood donation;\n23. Those with a history of fainting, blood, or difficult to collect blood or unable to tolerate venipuncture blood collection;\n24. Those who have participated in any clinical trial within 3 months prior to screening and have received investigational drugs or used investigational devices; or those who plan to participate in other clinical trials during this study;\n25. Those who have received vaccination within 4 weeks prior to screening or plan to receive vaccination during the trial to 1 month after the end of the trial.",true,"MALE","18 Years","45 Years",{"count":54,"type":55},8,"ESTIMATED","INTERVENTIONAL",[58],"PHASE1","This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of \\[14C\\] LPM3770164.",[61],"Huntington Disease","NOT_YET_RECRUITING","2026-04-01",{"date":65,"type":66},"2026-04-08","ACTUAL",{"date":68,"type":55},"2026-04-30",{"date":70,"type":55},"2026-07-30",{"name":5,"class":6},1]